Royalty Pharma Plc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BMVP7Y09
  • NASDAQ: RPRX
USD
58.52
0.08 (0.14%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Incyte Corp.
Viatris, Inc.
Alnylam Pharmaceuticals, Inc.
Bristol Myers Squibb Co.
Vertex Pharmaceuticals, Inc.
Zoetis, Inc.
Regeneron Pharmaceuticals, Inc.
Royalty Pharma Plc
Walgreens Boots Alliance, Inc.
Horizon Therapeutics Plc
Seagen Inc.

Why is Royalty Pharma Plc ?

1
Poor long term growth as Operating profit has grown by an annual rate -0.46% of over the last 5 years
  • INTEREST(HY) At USD 187.34 MM has Grown at 39.88%
  • INTEREST COVERAGE RATIO(Q) Lowest at 143.58
  • CASH AND EQV(HY) Lowest at USD 1,445.28 MM
2
Reducing Promoter Confidence
  • Promoters have decreased their stake in the company by -0.56% over the previous quarter and currently hold 0.34% of the company
  • Promoters decreasing their stake may signify reduced confidence in the future of the business
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Royalty Pharma Plc for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Royalty Pharma Plc
63.19%
4.84
23.46%
S&P 500
16.0%
1.22
13.15%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
2.30%
EBIT Growth (5y)
-0.46%
EBIT to Interest (avg)
7.51
Debt to EBITDA (avg)
3.87
Net Debt to Equity (avg)
0.97
Sales to Capital Employed (avg)
0.16
Tax Ratio
0
Dividend Payout Ratio
49.40%
Pledged Shares
0
Institutional Holding
92.22%
ROCE (avg)
12.61%
ROE (avg)
21.49%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
4.13
EV to EBIT
22.48
EV to EBITDA
22.45
EV to Capital Employed
2.37
EV to Sales
14.74
PEG Ratio
1.42
Dividend Yield
2.01%
ROCE (Latest)
10.54%
ROE (Latest)
20.08%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 3,011.45 MM

DIVIDEND PAYOUT RATIO(Y)

Highest at 587.5%

DIVIDEND PER SHARE(HY)

Highest at USD 2.83

NET SALES(Q)

Highest at USD 674.14 MM

RAW MATERIAL COST(Y)

Fallen by -9,981% (YoY

-18What is not working for the Company
INTEREST(HY)

At USD 187.34 MM has Grown at 39.88%

INTEREST COVERAGE RATIO(Q)

Lowest at 143.58

CASH AND EQV(HY)

Lowest at USD 1,445.28 MM

OPERATING PROFIT(Q)

Lowest at USD 134.41 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 19.94 %

PRE-TAX PROFIT(Q)

Lowest at USD 47.21 MM

NET PROFIT(Q)

Lowest at USD -16.39 MM

EPS(Q)

Lowest at USD 0.04

Here's what is working for Royalty Pharma Plc

Net Sales
Highest at USD 674.14 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Dividend per share
Highest at USD 2.83 and Grown
In each year in the last five years
MOJO Watch
Company is distributing higher dividend from profits generated

DPS (USD)

Operating Cash Flow
Highest at USD 3,011.45 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Dividend Payout Ratio
Highest at 587.5% and Grown
In each year in the last five years
MOJO Watch
Company is distributing higher proportion of profits generated as dividend

DPR (%)

Raw Material Cost
Fallen by -9,981% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 1.29 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Royalty Pharma Plc

Pre-Tax Profit
At USD 47.21 MM has Fallen at -86.33%
over average net sales of the previous four periods of USD 345.31 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -16.39 MM has Fallen at -107.72%
over average net sales of the previous four periods of USD 212.3 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest Coverage Ratio
Lowest at 143.58
in the last five periods
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest
At USD 187.34 MM has Grown at 39.88%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Profit
Lowest at USD 134.41 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin
Lowest at 19.94 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit
Lowest at USD 47.21 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -16.39 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

EPS
Lowest at USD 0.04
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Cash and Eqv
Lowest at USD 1,445.28 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Footer loading